Obstructive sleep apnea hypopnea syndrome
Conditions
Interventions
1. Dexmedetomidine + Sufentanil + Propofol Group (Group D):Dexmedetomidine + Sufentanil + Propofol
2. Midazolam + Sufentanil + Propofol Group (Group M):Midazolam + Sufentanil + Propofol Group
3. Remimazolam + Sufentanil + Propofol Group (Group R):Remimazolam + Sufentanil + Propofol
Sponsors
Beijing Friendship Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1 The subjects voluntarily participate in the study and sign the informed consent form on their own free will. 2 Aged 18–65 years, with no gender limitation. 3 Patients with a confirmed diagnosis of snoring and a spontaneous oxygen saturation (SpO2) of more than 95% while awake. 4 Complete examinations such as polysomnography (PSG) have been conducted before surgery.
Exclusion criteria
Exclusion criteria: 1 Subjects with sinus bradycardia or second-third degree atrioventricular block indicated by electrocardiogram (ECG). 2 Subjects with a history of pregnancy, lactation, poorly controlled hypertension, coronary heart disease, cerebrovascular disease, chronic obstructive pulmonary disease (COPD), glaucoma, myasthenia gravis, etc. 3 Subjects who have undergone surgical treatment for snoring or have received oral, cranial or cervical surgery within the recent 3 months. 4 Subjects with a history of allergy to relevant drugs such as dexmedetomidine, midazolam, remimazolam or propofol.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| ecord of the Occurrence and Management Measures of Respiratory Events;hemodynamic parameters;Others;satisfaction score;PACU-related Indicators: Sedation Score;Incidence of Perioperative Adverse Reactions;Health Economics Indicators; | — |
Primary
| Measure | Time frame |
|---|---|
| the ED50 and ED95 doses of propofol; | — |
Countries
China
Contacts
Public ContactYating Du
Beijing Friendship Hospital, Capital Medical University
Outcome results
None listed